Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ANG003 versus Creon in exocrine pancreatic insufficiency due to cystic fibrosis
MOH_2026-07-01_016912Phase 2Not yet recruiting
- Sponsor
- Anagram Therapeutics
- Start
- Jun 2026
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ANG003 in cystic fibrosis (CF) (4 arms), sponsored by Anagram Therapeutics. Primary endpoint: Not reported. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ANG003
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on MOH_2026-07-01_016912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-07-01_016912.